Hemolysis Overview
Learn About Hemolysis
Red blood cells normally live for 110 to 120 days. After that, they naturally break down and are most often removed from the circulation by the spleen.
Some diseases and processes cause red blood cells to break down too soon. This requires the bone marrow to make more red blood cells than normal. The balance between red blood cell breakdown and production determines how low the red blood cell count becomes. If the red blood cell count becomes abnormally low, it is called hemolytic anemia.
Conditions that can cause hemolysis include:
- Immune reactions
- Infections
- Medicines
- Toxins and poisons
- Red blood cell metabolism or defects in the shape of blood cells
Hemolysis is the breakdown of red blood cells.
Cleveland Clinic Main Campus
Jaroslaw Maciejewski is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Maciejewski and is rated as an Elite provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Splenectomy.
University Of Pittsburgh Physicians
Enrico Novelli is a Hematologist in Pittsburgh, Pennsylvania. Dr. Novelli and is rated as a Distinguished provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.
University Of Pittsburgh Physicians
Christine Leeper is a General Surgeon in Pittsburgh, Pennsylvania. Dr. Leeper and is rated as an Advanced provider by MediFind in the treatment of Hemolysis. Her top areas of expertise are Hemolytic Transfusion Reaction, Low Blood Pressure, Hemolysis, Gallbladder Removal, and Hernia Surgery.
Summary: Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic...
Summary: Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. Th...
Published Date: March 31, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Elghetany MT, Banki K. Erythrocytic disorders. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Philadelphia, PA: Elsevier; 2022:chap 33.
Gallagher PG. Red blood cell membrane disorders. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 46.
Gallagher PG. Hemolytic anemias: red blood cell membrane and metabolic defects. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 147.
Gregg XT, Prchal JT. Red blood cell enzymopathies. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 45.
Mentzer WC, Schrier SL. Extrinsic nonimmune hemolytic anemias. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA: Elsevier; 2023:chap 48.
Michel M. Autoimmune and intravascular hemolytic anemias. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 146.